Emerging Company Showcase

Transformative Innovations, Visionary Founders 

Each company featured in the 2024 Emerging Company Showcase was nominated, reviewed and invited to present based upon their transformative innovations and the enterprising team. They presented before a panel of ‘Pitch Doctors’, early stage VCs and investors, corporate VCs, strategic partners and other investors and advisors, who provide critical feedback and actionable guidance.

2024 Presenting Companies

	7 Hills Pharma, LLC, Research Triangle Park, NC: Developing first-in-concept integrin activators to augment immunotherapies for the treatment of drug resistant solid tumors and infectious diseases.
	Avanti Biosciences, San Diego, CA: Developing catechins derived small molecule compounds for the treatment of idiopathic pulmonary fibrosis (IPF), Alzheimer’s disease (AD), and nonalcoholic steatohepatitis (NASH).
	Calder Biosciences Inc., Brooklyn NY: Developing novel conformationally stabilized prefusion subunit vaccines for respiratory syncytial virus (RSV) and Influenza.
	Cell BioEngines, Inc, New York, NY: developing allogeneic “off-the-shelf” stem cell and its derived therapies for human disease treatment. Its lead product is currently in Phase 1 trials for the treatment of hematopoetiic neoplasms not curable with available therapies, particularly acute leukemia and myelodysplasia.
	Cellinfinity Bio, Inc., New Haven, CT: Developing the CLASH™ cell therapy platform to identify genetic modifications and CAR constructs to substantially improve engineered T-cell and NK-cell function against solid tumors.
	Cytonus Therapeutics, Carlsbad, CA: Developing transformative medicines based on next generation drug-delivery platform technology called Cargocytes™, a combination of precision drug delivery and in-vivo drug production.
	Egret Therapeutics Inc., New York, NY: Clinical-stage company leveraging immune checkpoint agonism to suppress inflammation and control innate immune responses to acute ischemic diseases.
	Energesis Pharmaceuticals Inc, Cambridge, MA: developing therapeutics for diabetes, obesity, and lipid disorders by targeting brown adipose tissue (BAT).
	Epitor Therapeutics, New York, NY: An epigenetic editing company targeting neurodevelopmental and neurodegenerative diseases with an initial target of Rett Syndrome.
	EpiVario Inc, Philadelphia, PA: Developing therapeutics targeting a newly identified epigenetic process involved in trauma-induced fear and stress responses, and addiction-related drug craving – It’s pharmacotherapeutic is designed to prevent relapse in opioid use disorder patients.
	Exposome Therapeutics, New York, NY: Targeting neurotransmitter storage as therapy for Parkinson’s disease.
	Flag Bio, Inc., Buffalo, NY: Developing proprietary mRNA adjuvant technology to enhance the efficacy, safety, and affordability of mRNA vaccines.
	Frezent Biological Solutions, New York, NY: Developing a novel class of bifunctional therapeutic modalities, bispecific antibodies and antibody-drug conjugates, to target non-dividing, dormant cancer cells.
	iCell Gene Therapeutics, Stony Brook, NY: Clinical-stage biotechnology company focused on the research and development of proprietary CAR immunotherapies for patients with unmet medical needs in autoimmune diseases and cancer.
	InLighta Biosciences, Marietta, GA: Developing protein-based contrast agents for pre-clinical and clinical imaging applications.
	Inomagen Therapeutics, Inc., Chicago, IL: Developing a non-viral gene therapy that targets the underlying mechanisms of Atrial Fibrillation.
	Kadence Bio, London, UK: Clinical-stage life sciences company developing novel therapeutics to address areas of significant unmet need in sexual and mental health.
	Kannalife, Inc., Doylestown, PA: Developing cannabinoid-inspired therapeutics as potent, non-opioid alternatives to treat patients with significant unmet medical needs
	Omios Biologics, Oakland, CA: Developing next-generation Immuno Gene Therapy to address the critical unmet need in solid tumor treatment.
	Perpetual Bio, New York, NY: Developing therapeutics for age-related diseases – Powered by a discovery platform that identifies novel regenerative medicine targets.
	Plakous Therapeutics, Inc., Winston-Salem, NC: Developing a biologic with anti-inflammatory and immunomodulatory capabilities that work together to orchestrate a complex cellular response to restore and repair organs damaged by inflammation-driven diseases.
	Pragma Bio, South San Francisco, CA: AI-enabled biology-first approach mines an untapped clinically-relevant source of novel small molecules to target the gut-immune axis for diverse clinical applications.
	Predictably Human, Inc, Darien, CT: Developing a digitally enabled, multimodal precision therapeutic platform (code name NoMore) for mental health and substance use disorders. NoMore represents a paradigm shift in care.
	Prolocor, Philadelphia,PA: Developing a diagnostic test that determines the risk of a thrombotic event in patients who have had a cardiovascular event.
	Rebel Medicine Inc, Salt Lake City, UT: Developing the next generation of long-acting local anesthetics that control pain locally for days, eliminating the need for opioids after surgery, and utilizing a clever design with extremely low COGS.
	Regnosine, Inc. New York, NY: Developing a disease-modifying regenerative therapy for osteoarthritis (OA) and other indications with unmet clinical needs utilizing a proprietary liposomal adenosine intraarticular injection.
	Serinus.Bio, New York, NY: Integrates computational biology and functional genomics to uncover the molecular landscape of treatment response or resistance, redefining precision in cancer therapeutics.
	SiVEC Biotechnologies, Fort Collins, CO: Developing delivery platform using non-pathogenic bacteria for targeted intracellular delivery of nucleic acid drugs and vaccines to mucosal epithelial cells.
	Terra Bioforge, Middleton WI: Developing a synthetic biology platform for manufacturing and discovering microbial natural products.
	TETmedical, Inc., Fair Haven, NJ: Platform diagnostic nanotechnology company developing a high sensitivity assay for ischemic stroke.
	Waypoint Bio. New York, NY: Developing novel cell therapies for solid tumors, autoimmune diseases, and beyond utilizing ultra-high resolution spatial multi-omics.
	Yaso Therapeutics Inc, Frisco, TX: developing antiviral solutions for treatment and prevention of HSV1 and HSV2drug products as well as a non-hormonal contraceptive.
	Zbeats, Stony Brook, NY: Developing a cloud-based platform and AI algorithms for ECG data acquisition, transmission, storage, visualization, and analysis.
	View the 2023 showcase presenters here.